

# The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis

---

**Bišof, Vesna; Zajc Petranović, Matea; Rakušić, Zoran; Samardžić, Kristina Ruža; Juretić, Antonio**

*Source / Izvornik:* **European Archives of Oto-Rhino-Laryngology, 2016, 273, 2305 - 2317**

**Journal article, Accepted version**

**Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)**

<https://doi.org/10.1007/s00405-015-3710-x>

*Permanent link / Trajna poveznica:* <https://um.nsk.hr/um:nbn:hr:105:486557>

*Rights / Prava:* [In copyright](#)/[Zaštićeno autorskim pravom.](#)

*Download date / Datum preuzimanja:* **2024-12-05**



*Repository / Repozitorij:*

[Dr Med - University of Zagreb School of Medicine  
Digital Repository](#)





## Središnja medicinska knjižnica

**Bišof V., Zajc Petranović M., Rakušić Z., Samardžić K. R., Juretić A.  
(2016) *The prognostic and predictive value of excision repair cross  
complementation group 1 (ERCC1) protein in 1288 patients with head  
and neck squamous cell carcinoma treated with platinum-based  
therapy: a meta-analysis.* European Archives of Oto-Rhino-  
Laryngology, 273 (9). pp. 2305-17. ISSN 0937-4477**

<http://www.springer.com/journal/405>

<http://link.springer.com/journal/405>

The final publication is available at Springer via  
<https://doi.org/10.1007/s00405-015-3710-x>

<http://medlib.mef.hr/2722>

University of Zagreb Medical School Repository

<http://medlib.mef.hr/>

The prognostic and predictive value of excision repair cross complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis

Vesna Bišof<sup>1</sup>, Matea Zajc Petranović<sup>2</sup>, Zoran Rakušić<sup>3</sup>, Kristina Ruža Samardžić<sup>3</sup>, Antonio Juretić<sup>4</sup>

1 Department of Oncology, University Hospital Centre Zagreb, Kišpatičeva 12, Zagreb, School of Medicine, University of Osijek, Croatia

2 Institute for Anthropological Research, Ljudevita Gaja 32, Zagreb, Croatia

3 Department of Oncology, University Hospital Centre Zagreb, Kišpatičeva 12, Zagreb, Croatia

4 Department of Oncology, University Hospital Centre Zagreb, Kišpatičeva 12, Zagreb, School of Medicine, University of Zagreb, Croatia

Corresponding author:

Vesna Bišof, MD, PhD

Department of Oncology

University Hospital Centre Zagreb

Kišpatičeva 12, 10 000 Zagreb

School of Medicine, University of Osijek

Croatia

Tel: +385 1 2388 579

e-mail: vesna.bisof@zg.t-com.hr

## Abstract

Excision repair cross-complementation group 1 (ERCC1) protein has been extensively investigated as a prognostic and predictive factor for platinum-based treatment in head and neck squamous cell carcinoma (HNSCC) but with inconsistent results. We performed the present meta-analysis to better elucidate this issue in advanced HNSCC.

A literature search was conducted using the PubMed and Web of Science databases. The inclusion criteria were head and neck cancer patients with platinum-based treatment and evaluation of the correlation between ERCC1 expression and clinical outcomes [objective response rate (ORR), progression-free survival (PFS), and overall survival (OS), both unadjusted and adjusted estimates].

In high vs. low pooled analyses, high ERCC1 expression was associated with unfavourable OS (hazard ratio (HR) = 1.95, 95% confidence interval (CI) 1.18 – 3.21,  $p=0.009$ ), PFS (HR = 2.39, 95% CI 1.74 – 3.28,  $p=0.000$ ) and ORR (OR = 0.48, 95% CI 0.23 – 0.98,  $p=0.044$ ). In the subgroup analysis of adjusted OS estimates, ERCC1 was a predictor of shorter survival in Asians (HR = 3.13, 95% CI 2.09 – 4.70,  $p=0.000$ ) and Caucasians (HR = 2.02, 95% CI 1.32 – 3.07,  $p=0.001$ ) but of longer survival in South Americans (HR = 0.17, 95% CI 0.07 – 0.40,  $p=0.000$ ). Immunohistochemistry proved to be of predictive value irrespective of used antibody ( $p=0.009$ ). In the stratified analysis according to the tumor site, ERCC1 expression was associated with OS in nasopharyngeal cancer (HR = 2.72, 95% CI 1.79 – 4.13,  $p=0.000$ ).

ERCC1 has a potential to become predictive and prognostic factor enabling treatment tailoring in HNSCC patients.

Key words: ERCC1, platinum-based chemotherapy, HNSCC, chemoradiotherapy, meta-analysis

## Introduction

Head and neck squamous cell carcinoma (HNSCC) accounts for more than 550 000 new cases annually worldwide [1]. Cisplatin-based chemoradiotherapy (CRT) is the standard treatment for locoregionally advanced disease both in case of unresectable disease as well as in case of resectable disease when organ preservation is desired [2-4]. Cisplatin is also a part of frequent induction chemotherapy schemes [4]. Besides, it is used in combination with postoperative radiotherapy (RT) in patients with high risk pathological findings [2]. Platinum agents bind to DNA and create DNA adducts which thus inhibit a cell cycle and lead to apoptosis [5]. However, platinum-based chemotherapy considerably increases treatment related toxicity. Regarding to the observation that some patients have modest response to the treatment or have no response at all, it is important to distinguish those among them who would actually benefit from the treatment. Therefore, identification of reliable biomarkers is of paramount importance for better selection of patients so that they would not be subjected to ineffective treatment and toxicity.

Excision repair cross-complementation group 1 (ERCC1) protein has been studied as a possible prognostic and predictive marker of response to platinum-based therapy since its discovery in the 1990s [6]. It belongs to the nucleotide excision repair (NER) system which has important role in repair of DNA. ERCC1 associates with xeroderma pigmentosum group F (XPF) protein to form a nuclease that function in DNA repair [7]. Besides ERCC1 plays a role in several other DNA repair pathways like homologous recombination [8], interstrand cross-link repair [9] and repair of DNA double-strand breaks (DSB) [10]. A correlation between level of ERCC1 expression and clinical outcomes of HNSCC patients treated with platinum-containing therapy has been investigated in numerous studies but the results were not consistent [11-15].

In an attempt to address this issue two meta-analyses has been published, one in the patients with HNSCC irrespective of the treatment modalities [16] and one in the patients treated with cisplatin-based concurrent CRT [17]. Since cisplatin-based chemotherapy is the part of different treatment modalities in patients with HNSCC we performed a systemic review and meta-analysis of studies outcomes to evaluate the prognostic and predictive value of ERCC1 expression in this category of patients.

## Materials and Methods

The present meta-analysis was performed according to PRISMA guidelines [18].

### Search strategy

PubMed and Web of Science databases were searched until January 4<sup>th</sup>, 2015. The keywords used in the online search were: “head and neck cancer”, “nasopharyngeal cancer”, “laryngeal cancer”, “oropharyngeal cancer”, “oral cavity cancer”, “hypopharyngeal cancer” and “ERCC1”. Only full-text papers written in English were included.

Eligibility criteria were: 1) human-based studies; 2) pathologically confirmed head and neck cancer; 3) platinum-based chemotherapy; 4) results of objective response rate (ORR), progression-free survival (PFS) and unadjusted and/or adjusted hazard ratio (HR) estimates for overall survival (OS) stratified by ERCC1 expression.

## Data extraction

The following data were extracted from the selected studies: the first author's name, year of publication, country of origin, ethnicity, sample size, stage of disease, tumor site, treatment, chemotherapy regimen, detection method of ERCC1 expression, number of ERCC1 high expression patients, number of ERCC1 low expression patients, clinical outcomes, covariates utilized in multivariate analyses of OS. When the direct HRs and their 95% CIs were not reported in the studies they were estimated using the method of Tierney et al. [19].

## Statistical analysis

The odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated to estimate the association between ERCC1 status and the ORR to treatment containing platinum-based chemotherapy in head and neck patients. The hazard ratios (HRs) and 95% CIs were employed to evaluate the relationship between ERCC1 expression and PFS and OS. Heterogeneity between studies was assessed by the  $I^2$  statistics. In the presence of heterogeneity between studies, a random-effect model was used instead of a fixed model [20-21]. Subgroup analyses by ethnicity (Asian, Caucasian and South American), detection method [8F1, other immunohistochemistry (IHC), reverse transcription-polymerase chain reaction (RT-PCR)] and tumor site (nasopharynx, mixed tumor sites not including nasopharynx and mixed tumor sites including nasopharynx) were also performed. Publication bias was tested by Beggs's and Egger's tests. All statistical analyses were carried out using STATA version 12 (Stata Corporation, College Station, TX, USA).

## Results

### Eligible studies

One hundred and twenty-seven potentially relevant articles were identified with keywords in the initial search (Supplementary Fig. 1). Ten articles were excluded because they were duplicates, and 41 after reading the titles and abstracts: 76 full-text articles were assessed for eligibility. Among them further 7 articles were excluded because of the following reasons: insufficient data ( $n = 3$ ); without platinum-based chemotherapy ( $n = 2$ ); highly selected population of patients ( $n = 2$ ) i.e. ERCC1 expression stratified by human papillomavirus (HPV) status in head and neck cancers. At the end, 17 studies containing 1288 patients were included in meta-analysis [11-15, 22-33].

Baseline characteristics of included studies were presented in details in Table 1. Studies were published between 2007 and 2014 and sample sizes of datasets ranged from 26 to 176. Nine studies were conducted in Caucasian patients [13-15, 23-25, 27-28, 30], seven studies in Asian patients [22, 26, 28-29, 32-33] and one in South American patients [11].

In 4 studies ERCC1 expression was determined by more than one method of detection in the same population of patients [11, 14-15, 23]. Three studies employed RT-PCR along with IHC [11, 15, 23]. Among IHC employing studies distinction was made between the most frequently used 8F1 antibody and other IHC methods. In two studies other IHC methods were employed along with 8F1 [14, 15] and in two further studies other antibodies were used alone [27, 30]. In this meta-analysis different methods of detection of the ERCC1 expression were treated as separate datasets leading thus to the total number of 1427 analyzed tissue samples. Marked heterogeneity was observed between thresholds used to separate high and low ERCC1 expression (Table 1).

### Objective response rate

Tumor response stratified by ERCC1 expression was reported by 10 datasets containing 587 head and neck patients, of whom 332 (57%) had high ERCC1 expression [12-13, 22-26, 29-30, 32]. In the pooled analysis, low ERCC1 expression was associated with better ORR to the treatment containing platinum-based chemotherapy (OR = 0.48, 95% CI = 0.23 – 0.98;  $I^2 = 56.5\%$ ,  $p = 0.014$  for heterogeneity; Table 2 and Fig. 1). No significant bias was found by the Begg's ( $p = 0.79$ ) and Egger's test ( $p = 0.53$ ) (Supplementary Fig. 2). In the sensitivity analysis, no individual study significantly affected the OR.

Subgroup analyses were done according to ethnicity, method of the detection and tumor site. Six studies were performed in Asians containing 357 patients [12, 22, 26, 29-30, 32], while four studies were conducted in Caucasians containing 230 patients [13, 23-25]. Low ERCC1 was associated with better ORR in Asian patients (OR = 0.29, 95% CI = 0.17 – 0.52;  $I^2 = 31.7$ ) while there was no association between ERCC1 expression and response to chemotherapy containing treatment in Caucasian patients (OR = 0.81, 95% CI = 0.40 – 1.67;  $I^2 = 65.3\%$ ) (Table 2 and Fig. 2). In eight datasets the ERCC1 expression was detected by IHC – 8F1 [12-13, 20-21, 23-24, 27, 30], in one by some other IHC method [28] and in another one by RT-PCR [21]. Low ERCC1 expression identified by IHC-8F1 was associated with better ORR (OR = 0.38, 95% CI = 0.23 – 0.61;  $I^2 = 35.3\%$ ) (Table 2). The association between low ERCC1 expression and better ORR was not influenced by tumor site since low ERCC1 expression was found to be a predictor of better ORR both in nasopharyngeal cancer group and in group of mixed tumor sites without nasopharyngeal cancer (Table 2).

### Progression-free survival

The association between ERCC1 expression and PFS was explored in seven datasets containing 430 patients, of whom 226 (53%) had high ERCC1 expression [12, 14, 22, 24, 30]. The pooled analysis showed that high ERCC1 expression was associated with shorter PFS for head and neck patients receiving platinum-based chemotherapy (HR = 2.39, 95% CI = 1.74 – 3.28;  $I^2 = 0.0\%$ ,  $p = 0.47$  for heterogeneity) (Table 2, Fig. 2). No significant bias was found by the Begg's test ( $p = 0.88$ ) and Egger's test ( $p = 0.42$ ) (Supplementary Fig. 3).

High ERCC1 expression was associated with unfavorable PFS both in Asians (HR = 3.33, 95% CI = 2.04 – 5.44;  $I^2 = 0.0\%$ ) and Caucasians (HR = 1.89, 95% CI = 1.25 – 2.85;  $I^2 = 0.0\%$ ). Moreover, in all subgroup analyses high ERCC1 expression was associated with shorter PFS in HNSCC patients receiving platinum-based chemotherapy irrespective of the ERCC1 expression detection method and tumor site (Table 2).

### Overall survival

Fifteen studies composed of 940 patients, of whom 530 (56%) were with high ERCC1 expression, reported data on adjusted estimates of OS (Table 2) [11-13, 15, 22, 24-26, 28-30, 32-33]. The covariates reported in included studies were: age and TNM stage in all studies, site [11-13, 15, 25], sex [11, 22, 26, 30], tumor differentiation [11, 13, 25, 30], performance status [28, 30], histologic type [29, 33], smoking [15, 22], alcohol drinking [22], betel nuts chewing [22], HPV status [15], treatment methods [28, 33], resection margin [11], extracapsular spreading [11], previous RT [30], relapse interval [30] and phosphor-mTOR expression [28]. The

pooled analysis showed that high ERCC1 expression was associated with shorter OS (HR = 1.95, 95% CI = 1.18 – 3.21,  $I^2 = 70.8\%$ ,  $p = 0.000$  for heterogeneity) (Table 2). No significant bias was found by the Begg's test ( $p = 0.22$ ) and Egger's test ( $p = 0.84$ ) (Supplementary Fig. 4). High ERCC1 expression was a predictor of shorter OS both in Asians and Caucasians (HR = 3.13, 95% CI 2.09 – 4.70;  $I^2 = 0.0\%$  and HR 2.02, 95% CI 1.32 – 3.07;  $I^2 = 23.7\%$  respectively) (Table 2, Fig. 3a). On the contrary, the study conducted in South America [11] in which ERCC1 expression was identified by IHC and RT-PCR, revealed that high ERCC1 expression was associated with better OS (HR = 0.17, 95% CI 0.07 – 0.40;  $I^2 = 0.0\%$ ).

Subgroup analysis based on a detection method showed association between better survival and low ERCC1 expression determined by 8F1 and other immunohistochemistry methods while it was not the case with RT-PCR (Table 2). In the stratified analysis according to tumor site ERCC1 expression was related to OS in nasopharyngeal cancer, but not in the group of mixed head and neck tumors with or without nasopharyngeal cancer (Table 2, Fig. 3b).

Fourteen studies composed of 952 patients, of whom 463 (49%) were with high ERCC1 expression, reported data on unadjusted estimates of OS (Table 2) [11-13, 15, 22, 27, 29-30, 32-33]. In the pooled analysis of unadjusted HR estimates of OS no association was found between ERCC1 expression and OS (HR = 1.10, 95% CI 0.76 – 1.59;  $I^2 = 55.9$ ,  $p = 0.01$  for heterogeneity) (Table 2). No significant bias was found by the Begg's test ( $p = 0.27$ ) and Egger's test ( $p = 0.08$ ) (Supplementary Fig. 5). However, in subgroup analysis based on ethnicity, low ERCC1 expression was predictor of better OS in Asians but not in Caucasians (HR = 2.13, 95% CI 1.27 – 3.59;  $I^2 = 0.0\%$  and HR = 1.03, 95% CI 0.70 – 1.52;  $I^2 = 42.8\%$ ) while in South Americans high ERCC1 expression was a predictor of better survival (HR = 0.36, 95% CI 0.20 – 0.65;  $I^2 = 0.0\%$ ) (Table 2, Fig. 4). Even when the South American study with two datasets [11] was excluded from the analysis, there was still no association between ERCC1 expression and OS in the meta-analysis of unadjusted estimates. In the stratified analysis according to detection method and tumor site, no association was found between OS and ERCC1 expression (Table 2).

In the sensitivity analysis no individual study significantly affected the pooled OR in ORR and HR in PFS and OS.

## Discussion

The ERCC1-XPF heterodimer is a structure-specific endonuclease that is involved in several DNA repair mechanisms like interstrand cross-link repair, repair of DNA DSB and NER system. ERCC1 mediates DNA binding and protein-protein interactions of the ERCC1-XPF complex while XPF provides the endonuclease activity. Besides its important role in the multiple repair mechanisms the ERCC1-XPF is also involved in telomere maintenance. As the part of NER system the ERCC1-XPF incises the damaged DNA strands 5' and 3'. In the DSB repair the ERCC1-XPF removes non-homologous 3' single-strands flaps at broken ends before they are rejoined. The ERCC1-XPF incises both sides of interstrand cross-links (34). On the other hand, platinum based chemotherapy and radiotherapy which are basics of the treatment of HNSCC patients exert their cytotoxic effect through formation of DNA damages. Therefore, due to the important role in the DNA repair mechanisms the expression of the ERCC1 and its correlation with clinical outcomes of HNSCC patients



treated with platinum-containing therapy has been studied in large number of studies but with inconsistent results.

Results of present meta-analysis of 1288 patients and 1427 tissue samples indicated that high ERCC1 expression was significantly associated with shorter PFS and OS (when adjusted for covariates) in patients with HNSCC treated with cisplatin-based therapy. Low ERCC1 expression was also a significant predictor of better ORR. However, ethnicity and tumor site arose as important factors. Interestingly ERCC1 expression was not a predictor of OS in the analysis of unadjusted HR estimates.

Xuelei et al. [16] reported that ERCC1 expression was associated with OS in the pooled HRs analysis and in Asians while ERCC1 expression was not a predictor of the ORR in the whole cohort of patients except in Asians. Low/negative expression of ERCC1 was associated with longer OS and PFS in patients treated with cisplatin-based CRT, but there was no significant difference in ORR between low/negative and high/positive ERCC1 expression [17]. What are differences and similarities between these two meta-analyses and our meta-analysis? Firstly, the relationship between high ERCC1 expression and resistance to platinum-based chemotherapy has been better established for lung and ovarian cancer than for head and neck cancer. There is a considerable heterogeneity between reported results in head and neck patients. Whereas the literature on ERCC1 and radiotherapy is very scarce and the evidence for that relation has not been robust especially in clinical settings, we think it is of great importance to analyze separately treatments including platinum-based chemotherapy and radiotherapy alone [35-37]. Besides it was reported that although ERCC1 positive cells showed increased chemoresistance they might have been particularly radiosensitive and less hypoxic [38]. Xuelei et al. [16] included in their meta-analysis all studies irrespective of treatment modality, while Gao et al. [17] included studies dealing with cisplatin-based chemoradiotherapy. We included all the studies with treatments containing platinum-based chemotherapy. Moreover, we presume that there may be a difference between ERCC1 expression and clinical outcome in neoadjuvant and adjuvant treatment. Namely, results of the study from South America with two datasets [11] quite differ from results of the majority of other studies and the reason for that may be ethnicity but also the fact that it was the only study with adjuvant treatment.

Secondly, wide heterogeneity of detection methods has been reported in studies under consideration [11-15, 22-33]. It has been shown that ERCC1 immunodetection faces several methodological challenges including tissue processing, rates of interobserver agreement, geographic variation in protein expression and, most importantly, lack of the standardized cutoff value in semi-quantitative IHC [39-41]. It has been also reported that the most frequently used antibody 8F1 has not been specific for ERCC1 [42]. It also tags a spurious 45 kDa band on immunoblotting, a cross reaction that results in ERCC1-XPF deficient cells being falsely characterized as having ERCC1-XPF expression [43], and the unrelated nuclear membrane protein choline phosphate cytidylyltransferase- $\alpha$  (PCYT1  $\alpha$ ) [44-45]. Fiboulet et al. [46] reported that the major limitation to ERCC1 employment in guiding the treatment decision was the lack of ERCC1 antibodies that would detect functionally different ERCC1 isoforms. The ERCC1-202 was identified as the unique functional isoform of ERCC1. Therefore, in our meta-analysis stratification according to detection method was applied. ERCC1 immunodetection was associated with ORR, PFS and OS (adjusted HR estimates) irrespective of different antibodies and different cutoff values. However, no association was found for RT-PCR. It is in accordance with the report of Fiboulet et al. [46]. Despite the fact that RT-PCR was more quantitative analysis of ERCC1 than IHC, a predictive potential of ERCC1 appeared to be stronger at a protein level [46].

Thirdly, in our meta-analysis we performed subgroup analysis based on tumor site which was not a case in the meta-analysis of Xuelei et al. [16]. Low ERCC1 expression was associated with better ORR in nasopharyngeal cancer and in the group of mixed head and neck cancers without nasopharyngeal cancer but ERCC1 expression was associated with overall survival (adjusted HR estimates) only in nasopharyngeal cancer group. Probably, high heterogeneity ( $I^2 = 80.5\%$ ) of the mixed head and neck cancer group was responsible for the lack of the association between ERCC1 expression and OS in that group. Gao et al.[17] also reported that ERCC1 expression was a predictor of OS in patients with nasopharyngeal carcinoma.

Fourthly, Xuelei et al. [16] used multivariate and univariate data together while we performed separate meta-analyses of univariate and multivariate data for OS. We used only univariate data for PFS since multivariate data are scarce.

Although sharing some similarities with the meta-analysis of Gao et al. [17] our analysis of adjusted OS estimates included larger sample size of 940 patients from 15 studies while the study of Gao et al. [17] included 568 patients from 9 studies.

Both meta-analyses, that of Xuelei et al. [16] and the present one, found strong association between ERCC1 expression and ORR and OS in Asian population. Gao et al. [17] also reported that ERCC1 expression was a predictor of OS in Asians but not in non-Asians. In our analysis of unadjusted and adjusted HR estimates, ERCC1 expression was significantly associated with OS in Asians while in Caucasians significant association was found only in the analysis of adjusted HR estimates. In the analysis of Xuelei et al. [16] ERCC1 expression was not associated with OS in Caucasians. Low ERCC1 expression was strong prognostic factor of better PFS in all three meta-analyses.

Our meta-analysis has several limitations. Firstly, the included studies differed considerably in study design, cutoffs in ERCC1 expression, treatment scheme and chemotherapy regimen contributing thus to the observed heterogeneity. Secondly, 8F1 was the most frequently used antibody for ERCC1 expression, and in the light of new knowledge about this antibody caution is needed not only in the interpretation of results of the study, but also in its possible implementation in the clinical setting. Thirdly, the majority of included studies are of small sample size with only 4 of them having more than 100 patients, which may contribute to the heterogeneity. Only one randomized study and one extension of the randomized study were identified. Fourthly, it is possible that calculations of HR estimates and corresponding 95% CIs from Kaplan Mayer's curves also contributed to heterogeneity and bias.

The results of this meta-analysis provided evidence that ERCC1 has a potential to become predictive and prognostic factor enabling tailoring of treatment in patients with HNSCC. However, considering limitations of this analysis and rapidly expanding scientific knowledge about the ERCC1, our findings need to be interpreted with caution. The standardized methodology of ERCC1 expression determination and well-designed prospective randomized studies are needed before its implementation in everyday clinical practice.

Conflict of interest: None

## References:


1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. *CA Cancer J Clin* 65:87-108
2. Gregoire V, Lefebvre J-L, Licitra L, Felip E (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 21(suppl. 5):vi184-6.
3. Tang C, Chan C, Jiang W, Murphy JD, von Eyben R, Colevas AD, Pinto H, Lee-Enriquez N, Kong C, Le QT (2015) Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. *Head Neck* 37:386-92
4. Pignon JP, le Maître, Maillard E, Bourhis J; MACH-NC Collaborative Group (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomized trials and 17,346 patients. *Radiother Oncol* 92:4-14
5. Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G (2014) Systems biology of cisplatin resistance: past, present and future. *Cell Death Dis.* doi:10.1038/cddis.2013.428
6. Damia G, Imperatori L, Stefanini M, D'Incalci M (1996) Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anticancer agents. *Int J Cancer* 66:779-83
7. Bowden NA (2014) Nucleotide excision repair: Why is it not to predict response to platinum-based chemotherapy? *Cancer Lett* 346:163-71
8. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NGJ, Berna Beverloo H, Hoeijmakers JHJ, Kanaar R (2004) The structure-specific endonuclease ERCC1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. *Mol Cell Biol* 24:5776-87
9. Bergstralh DT, Sekelsky J (2008) Interstrand crosslink repair: can XPF-ERCC1 be let off the hook? *Trends Genet* 24:70-6
10. Ahmad A, Robinson AR, Duensing A, van Drunen E, Berna Beverloo H, Weisberg H, Hasty P, Hoeijmakers JHJ, Niedernhofer LJ (2008) ERCC1-XPF endonuclease facilitates DNA double-strand break repair. *Mol Cell Biol* 28:5082-92
11. De Castro G Jr, Pasini FS, Siqueira SA, Ferraz AR, Villar RC, Snitcovsky IM, Federico MH (2011) ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. *Oncol Rep* 25:693-9
12. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong H-S, Son Y-I, Baek J-H, Park K (2008) ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. *Br J Cancer* 99:167-72
13. Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE (2012) ERCC1 expression and outcome in head and neck cancer treated with concurrent cisplatin and radiation. *Anticancer Res* 31:4135-40

14. Bauman JE, Austin MC, Schmidt R, Kurland BF, Vaezi A, Hayes DN, Mendez E, Parvathaneni U, Chai X, Sampath S, Martins RG (2013) ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomized, phase II trial. *Br J Cancer* 109:2096-105
15. Hao D, Lau HY, Eliasziw M, Box A, Diaz R, Klimowicz AC, Shin B, Lees-Miller S, Magliocco AM (2012) Comparing ERCC1 protein expression, mRNA levels and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status. *Head Neck* 34:785-91
16. Xuelei M, Jingwen H, Wei D, Hongyu Z, Jing Z, Changle S, Lei L (2015) ERCC1 plays an important role in predicting survival outcomes and treatment response for patients with HNSCC: A meta-analysis. *Oral Oncol* 51:483-92
17. Gao Y, Liu D (2015) The roles of excision repair cross-complementation group 1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancer: A systematic review and meta-analysis. *Oral Oncol* 51:570-577
18. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group (2009) Preferred reporting items for systemic reviews and meta-analyses: the PRISMA statement. *PLoS Med.*  
doi:10.1371/journal.pmed.1000097
19. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes M (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials.* doi:10.1186/1745-6215-8-16
20. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. *Control Clin Trials* 7:177-88
21. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 22:719-48
22. Chiu T-J, Chen C-H, Chien C-Y, Li S-H, Tsai H-T, Chen Y-J (2011) High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in betel-chewing area. *J Transl Med.* doi:10.1186/1479-5876-9-31
23. Fountzilias G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolaou A, Karayannopoulou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Asravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D (2009a) MMP9 but not EGFR, MET, ERCC1, P16 and P-53 is associated with response to concomitant radiotherapy, cetuximab and weekly cisplatin in patients with locally advanced head and neck cancer. *J Oncol.* doi:10.1155/2009/305908
24. Fountzilias G, Bamias A, Kalogera-Fountzila A, Karayannopoulou G, Bobos M, Athanassiou E, Kalogeras KT, Tolis C, Tsekeris P, Papakostas P, Vamvouka C, Zaramboukas T, Kosmidis P, Zamboglou N, Misailidou D (2009b) Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck. *Anticancer Res* 29:529-38.
25. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria J-C, Fouret P (2007) Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. *Clin Cancer Res* 13:3855-9


26. Huang P-Y, Li Y, Mai H-Q, Luo R-Z, Cai Y-C, Zhang Li (2012) Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin –based induction chemotherapy. *Oral Oncol* 48:964-8
27. Jagdis A, Phan T, Klimowicz AC, Laskin JJ, Lau H, Petrillo SK, Siever JE, Thomson TA, Magliocco AM, Hao D (2013) Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment. *Int J Radiation Oncol Biol Phys* 85:1340-5
28. Krikelis D, Bobos M, Karayannopoulou G, Resiga L, Chrysafi S, Samantas E, Andreopoulos D, Vassiliou V, Cluleanu E, Fountzilias G (2013) Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients. *BMC Clin Pathol*. doi:10.1186/1472-6890-13-1
29. Lee HW, Hwang YH, Han HJH, Choi J-H, Kang SY, Jeong SH, Ann MS, Oh YT, Kim JH, Kim CH, Sheen SS (2010) High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer. *Oral Oncol* 46:209-13
30. Park Y, Kim DS, Park KH, Baek S-K, Kwon SY, Shin SW, Jung KY, Kim CY, Kim YH, Lee NJ, Kim JS, Kim IS (2012) RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin. *Onkologie* 35:673-82
31. Patel MR, Zhao N, Ang M-K, Stadler ME, Fritchie K, Weissliet MC, Zanation AM, Harris SL, Funkhouser WK, Olshan AF, Shores CG, Hayes DN (2013) ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma. *Otolaryngol Head Neck Surg* 149:587-95
32. Sun J-M, Ahn M-J, Park MJ, Lee H-Y, Ahn JS, Lee S, Kang G, Han J, Son Y-I, Baek C-H, Ahn YC, Park K (2011) Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. *Int J Radiation Oncology Biol Phys* 80:655-60
33. Zhang Z, Jiang C, Hu L (2014) Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy. *Tumori* 100:328-32
34. McNeil EM, Melton DW (2012) DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. *Nucleic Acids Res* 40:9990-10004
35. Nix P, Greenman J, Cawkwell L (2004) Expression of XRCC1 and ERCC1 proteins in radioresistant and radiosensitive laryngeal cancer. *Cancer Therapy* 2:47-53
36. Johung KL, Rewari A, Wu H, Contessa J, Haffty B, Decker RH (2013) Role of excision repair cross-complementation 1 expression as a prognostic marker for response to radiotherapy in early stage laryngeal cancer. *Head Neck* 35:852-7
37. Bišof V, Jakovčević A, Seiwerth S, Rakušić Z, Gašparov S (2013) Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy. *J Cancer Res Clin Oncol* 139:187-94

38. Dudas J, Schartinger VH, Romani A, Schweigl G, Kordsmeyer K, Marta PI, Url C, Kral F, Riechelmann H (2014) Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer. *Tumor Biol* 35:7807-19
39. Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, Mountzios G, Validire P, Domont J, Girard P, Grunenwald D, Le Chevalier T, Soria JC (2007) Immunohistochemical expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small cell lung cancer. *Ann Oncol* 18:1043-50
40. Babic A, Loftin IR, Stanislaw S, Wang M, Miller R, Warren SM, Zhang W, Lau, A, Miller M, Wu P, Padilla M, Grogan TM, Pesrtic-Dragovich L, McElhinny AS (2010) The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization assays. *Methods* 52:287-300
41. Taylor CR, Levenson RM (2006) Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. *Histopathology* 49:411-24.
42. Niedernhofer LJ, Bhagwat N, Wood RD (2007) ERCC1 and non-small cell lung cancer. *N Engl J Med* 356:2538-40
43. Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, Niedernhofer LJ (2009) Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. *Cancer Res* 69:6831-8
44. Ma D, Baruch D, Shu Y, Yuan K, Sun Z, Ma K, Hoang T, Fu W, Min L, Lan ZS, Wang F, Mull L, He WW (2012) Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. *BMC Biotechnol*. doi:10.1186/1472-6750-12-88
45. Vaezi AE, Bepler G, Bhagwat NR, Malysa A, Rubatt JM, Chen W, Hood BL, Conrads TP, Wang L, Kemp CE, Niedernhofer LJ (2014) Choline phosphate cytidyltransferase- $\alpha$  is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas. *Cancer* 120:1898-907
46. Friboulet L, Olasussen KA, Pignon J-P, Shepherd FA, Tsao M-S, Graziano S, Kratzke R, Douillard J-Y, Seymour L, Pirker R, Filipits M, André F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria J-C (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. *N Engl J Med* 368:1101-10

**Fig. 1** Forest plot for the association between ERCC1 expression and objective response rate (ORR) in patients with head and neck cancer receiving platinum-based therapy. Results are stratified by ethnicity.




**Fig. 2** Forest plot showing the meta-analysis of unadjusted hazard ratio estimates for progression-free survival (PFS) in patients with head and neck cancer receiving platinum-based therapy.




**Fig. 3** Forest plot showing the meta-analysis of adjusted hazard ratio estimates for overall survival (OS) in patients with head and neck cancer receiving platinum-based therapy.

a) Results are stratified by ethnicity



b) Results are stratified by tumor site.





**Fig. 4** Forest plot showing the meta-analysis of unadjusted hazard ratio estimates for overall survival (OS) in patients with head and neck cancer receiving platinum-based therapy. Results are stratified by ethnicity.

